AI English summary of an SEC filing — figures as filed
Moderna MRNAModerna said its full-year 2023 net product sales of COVID-19 vaccines were $6.7 billion, compared with $18.4 billion in 2022 and $17.7 billion in 2021. Total revenue fell $12.4 billion (64%), and the company cited lower sales volume from the market's shift to a seasonal pattern as the reason for the decline.
Key points
AI summaryModerna said its full-year 2023 net product sales of COVID-19 vaccines were $6.7 billion, compared with $18.4 billion in 2022 and $17.7 billion in 2021. Total revenue fell $12.4 billion (64%), and the company cited lower sales volume from the market's shift to a seasonal pattern as the reason for the decline.
The company said it started cost structure optimization for its COVID-19 business in Q3 2023, and that its cost of sales for the full year was $4.7 billion, or 70% of net product sales (2022 29%). This included inventory write-downs of $2.2 billion.
Moderna said it had a net loss of $4.7 billion in 2023 (net income of $8.4 billion in 2022), and net cash used in operating activities of $3.1 billion. The company said operating cash flow could be negative in future periods.
The company said cash, cash equivalents and investments as of December 31, 2023 decreased $4.9 billion (27%) from the end of the prior year. For 2023, it repurchased shares of common stock for $1.2 billion and purchased property, plant and equipment for $707 million.
Key figures
Fiscal year ended December 31, 2023
- Revenue
- $6.8B
- Operating income
- −$4.2B
- Net income
- −$4.7B
- EPS
- −$12.33
- Operating cash flow
- −$3.1B
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
2023 COVID-19 vaccine net product sales of $6.7 billion
Moderna said its full-year 2023 net product sales of COVID-19 vaccines were $6.7 billion, compared with $18.4 billion in 2022 and $17.7 billion in 2021. Total revenue fell $12.4 billion (64%), and the company cited lower sales volume from the market's shift to a seasonal pattern as the reason for the decline.
Source · Based on the MD&A text of the filing
Cost structure optimization and cost of sales as a share of sales at 70%
The company said it started cost structure optimization for its COVID-19 business in Q3 2023, and that its cost of sales for the full year was $4.7 billion, or 70% of net product sales (2022 29%). This included inventory write-downs of $2.2 billion.
Source · Based on the MD&A text of the filing
2023 net loss and operating cash flow
Moderna said it had a net loss of $4.7 billion in 2023 (net income of $8.4 billion in 2022), and net cash used in operating activities of $3.1 billion. The company said operating cash flow could be negative in future periods.
Source · Based on the MD&A text of the filing
Cash and investments down at 2023 year-end, share buybacks
The company said cash, cash equivalents and investments as of December 31, 2023 decreased $4.9 billion (27%) from the end of the prior year. For 2023, it repurchased shares of common stock for $1.2 billion and purchased property, plant and equipment for $707 million.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
You can verify the report’s figures and statements in the original filing on SEC EDGAR.